Magnesiumsulfat Sad (Magnesium Sulfate)

Magnesium sulfate increases extracellular magnesium, which competes with calcium at voltage‑gated channels, producing vasodilation, reducing neuronal excitability, and stabilizing cardiac cell membranes. It also serves as a cofactor for many enzymes, helping restore normal physiological functions.

The specific dose and infusion rate of Magnesiumsulfat Sad are determined by the prescribing clinician based on the patient’s condition, serum magnesium level, renal function, and other clinical factors. Healthcare professionals set the appropriate regimen.

Magnesium sulfate may be used in pregnancy when the benefits outweigh potential risks, such as in eclampsia management. Its safety in breastfeeding is not fully established, so clinicians should evaluate the need and monitor the infant if treatment is continued.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Magnesiumsulfat Sad is an injectable magnesium sulfate formulation, offering rapid correction of magnesium deficits compared with oral salts that have slower absorption. It provides precise dosing for acute settings such as eclampsia or cardiac arrhythmias, whereas oral preparations are typically used for chronic supplementation.

Store the product below 25 °C in its original packaging, protecting it from moisture and direct sunlight. Ensure the vial or ampoule remains sealed until use, and follow standard aseptic techniques when preparing the intravenous solution.

Magnesiumsulfat Sad is given by intravenous infusion. The healthcare provider prepares the appropriate concentration in a compatible IV fluid and administers it over a controlled period, monitoring vital signs and serum magnesium levels throughout the infusion.

Serious risks include hypermagnesemia, which can cause respiratory depression, severe hypotension, cardiac arrest, and profound muscle weakness. Prompt monitoring of serum magnesium and clinical status is essential to detect and manage these complications early.

Patients with severe renal failure, uncontrolled heart block, or known hypersensitivity to magnesium sulfate should avoid this product. Additionally, individuals with existing hypermagnesemia or those receiving concurrent high‑dose magnesium preparations require careful evaluation before use.